<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.34848.005</object-id><label>Table 2.</label><caption><title>Number of participants who were seropositive to DENV in 2013 and 2015 as measured by ELISA and MIA.</title><p>MIA any DENV denotes participants who were MIA seropositive to at least one DENV serotype. 95% CI shown in parentheses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Test</th><th>N</th><th>2013</th><th>2013 (%)</th><th>2015</th><th>2015 (%)</th><th>Difference</th></tr></thead><tbody><tr><td>ELISA</td><td>263</td><td>154</td><td>58.6% (52.3&#8211;64.6%)</td><td>196</td><td>74.5% (68.8&#8211;79.7%)</td><td>16% (11.8&#8211;21%)</td></tr><tr><td>MIA any DENV</td><td>263</td><td>193</td><td>73.4% (67.6&#8211;78.6%)</td><td>216</td><td>82.1% (77&#8211;86.6%)</td><td>8.75% (5.62&#8211;12.8%)</td></tr><tr><td>MIA DENV-1</td><td>263</td><td>177</td><td>67.3% (61.3&#8211;72.9%)</td><td>198</td><td>75.3% (69.6&#8211;80.4%)</td><td>7.98% (5.01&#8211;11.9%)</td></tr><tr><td>MIA DENV-2</td><td>263</td><td>33</td><td>12.5% (8.8&#8211;17.2%)</td><td>41</td><td>15.6% (11.4&#8211;20.5%)</td><td>3.04% (1.32&#8211;5.91%)</td></tr><tr><td>MIA DENV-3</td><td>263</td><td>87</td><td>33.1% (27.4&#8211;39.1%)</td><td>140</td><td>53.2% (47&#8211;59.4%)</td><td>20.2% (15.5&#8211;25.5%)</td></tr><tr><td>MIA DENV-4</td><td>263</td><td>79</td><td>30.0% (24.6&#8211;36%)</td><td>99</td><td>37.6% (31.8&#8211;43.8%)</td><td>7.6% (4.71&#8211;11.5%)</td></tr></tbody></table></table-wrap>